Pituitary & hypothalamus

Descriptive analysis and outcomes of pituitary neuroendocrine tumours (PitNETs) treated surgically during pregnancy and postpartum

Eur J EndocrinolPublished Retrospective cohort study

Authors' conclusion

PitNETs requiring surgical treatment during pregnancy are characterized by increased proliferative activity and progression after surgery. Despite this, the long-term prognosis remains favourable.

Study context

Population
Women with PitNETs treated surgically, 5 university hospitals
Participants
10 vs 30
Exposure
PitNETs treated surgically during pregnancy/postpartum vs matched non-pregnant controls
  • Pregnantn = 10
  • Non-pregnant controlsn = 30reference
Outcome
Clinical, histological profiles and progression-free survival without additional treatment
Methodological detailsmulticentre, observational, matched controls
  • Multicentre
  • Observational
  • Matched controls

Main finding

As reported in the abstract

  • Pregnant vs Non-pregnant controls: P = 0.038
  • Pregnant vs Non-pregnant controls: P = 0.049
  • Pregnant vs Non-pregnant controls: P = 0.005

Observational data: associations, not effects.

Further findings

OutcomePregnantNon-pregnant controlsP value
Primary surgical indication: tumour syndrome ± failure of medical treatmentSimilar7/1019/30P = 1.00
Tumour volume and radiological invasion · volume; no significant difference
P = 0.072
Tumour volume and radiological invasion · optic chiasm compression; no significant difference
P = 0.059
Tumour volume and radiological invasion · cavernous sinus invasion; no significant difference
P = 0.274

PitNET type (pregnant)

Corticotropic
4
Gonadotropic
2
Lactotropic
2
Somatotropic
2

Original publication

Descriptive analysis and outcomes of PitNETs treated surgically during pregnancy and postpartum. Eur J Endocrinol. Published 8 February 2025. doi:10.1093/ejendo/lvaf018

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.